From our founding in 1987 to becoming a fully integrated pharmaceutical group with global reach, explore the milestones and achievements that define Shilpa Medicare's journey of innovation and excellence.
Founded in 1987 as an API manufacturer in Raichur, Karnataka, Shilpa Medicare has grown from a single facility to a fully integrated pharmaceutical group with global reach, robust R&D footprint, and advanced CDMO/biologics capabilities.
Commercial production began in November 1989, marking the start of our journey to become a leading pharmaceutical manufacturer serving patients worldwide.
Over the decades, Shilpa Medicare has strategically expanded beyond our API manufacturing roots into multiple pharmaceutical domains, establishing ourselves as an innovation-driven organization.
Expanded into diverse dosage forms including oral solids, injectables, and specialized delivery systems
Built high potency API capabilities with strict containment for cancer therapeutics
Developed expertise in technically challenging formulations and peptide APIs
Entered the biologics space with world-class R&D and pilot manufacturing capabilities
Established comprehensive contract development and manufacturing offerings
Formed collaborations for biologics, licensing, and global market access
USFDA inspections with zero 483 observations for API plants, demonstrating our unwavering commitment to quality and compliance
Opening of state-of-the-art transdermal patch and oral thin film facility, expanding our dosage form capabilities
Established strategic partnerships for biologics development, technology licensing, and global commercialization
Built multiple world-class R&D centers across India specializing in APIs, formulations, and biologics
Shilpa Medicare has been on a path of expansion ever since its inception in 1987. With a regulatory recognized manufacturing setup and excellent scientific expert team in place, Shilpa Medicare has been on a steady growth path for over three decades.
Currently, we are one of the leaders in the Oncology market and offer a complete range of products spanning across APIs, formulations, novel drug delivery systems, and biotech products.
Shilpa Antibiotics Ltd. established in Raichur, marking the beginning of Shilpa’s pharmaceutical journey.
Shilpa converted into a public company and listed on the Bombay Stock Exchange (BSE).
First patent filed, expansion of R&D capabilities, and recognition through multiple national export awards and ISO certifications.
Entry into oncology formulations with USFDA approvals for API and formulation facilities, first ANDA approvals, and EU Marketing Authorizations.
Strategic investments in biologics and novel drug delivery systems including oral thin films, transdermal systems, and specialty products.
Shilpa operates as an integrated global partner across APIs, formulations, oncology, and biologics with a growing CDMO focus.
Serving patients in over 40 countries across regulated and emerging markets
Four world-class R&D centers driving innovation across APIs, formulations, and biologics
Comprehensive contract development and manufacturing services for global partners
Advanced biologics R&D and cGMP pilot facility for biosimilars and novel biologics
USFDA, EMA, WHO-GMP approved facilities with zero tolerance for quality compromises
250+ patents filed demonstrating our commitment to innovation and IP development
From our humble beginnings in 1987 to our position today as a fully integrated pharmaceutical powerhouse, Shilpa Medicare remains committed to our founding vision: delivering high-quality, affordable medicines that improve lives globally. As we continue to innovate and expand, we stay true to the values that have guided us for over three decades.
